INSPECS GROUP PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 73.5 GBX | +3.52% |
|
-0.68% | -12.50% |
| Apr. 17 | AIM WINNERS & LOSERS: Inspecs confident but Scirocco eyes AIM exit | AN |
| Apr. 17 | Inspecs hails "encouraging" recent trading after tepid start to 2024 | AN |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The stock, which is currently worth 2024 to 0.45 times its sales, is clearly overvalued in comparison with peers.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -12.50% | 91.47M | C- | ||
| +22.00% | 44.19B | B | ||
| +2.38% | 19.46B | B- | ||
| -16.08% | 2.31B | D+ | ||
| +16.60% | 1.92B | C+ | ||
| +27.36% | 1.23B | - | ||
| -34.93% | 755M | - | ||
| -40.97% | 699M | B- | ||
| -6.32% | 677M | - | ||
| +28.48% | 510M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- SPEC Stock
- Ratings INSPECS Group plc
